[1]
|
Phillips, B.A., Collop, N.A., Drake, C., Consens, F., Vgontzas, A.N. and Weaver, T.E. (2008) Sleep Disorders and Medical Condition in Women. Proceedings of the Women and Sleep Workshop, National Sleep Foundation, Washington DC, 5-6 March 2007, Journal of Women’s Health, Larchmt, 17, 1191-1199.
http://dx.doi.org/10.1089/jwh.2007.0561
|
[2]
|
Ameratunga, D., Goldin, J. and Hickey, M. (2012) Sleep Disturbance in Menopause. Internal Medicine Journal, 42, 742-747. http://dx.doi.org/10.1111/j.1445-5994.2012.02723.x
|
[3]
|
Polo-Kantola, P. (2011) Sleep Problems in Midlife and Beyond. Maturitas, 68, 224-232.
http://dx.doi.org/10.1016/j.maturitas.2010.12.009
|
[4]
|
Gold, E., Colvin, A., Avis, N., et al. (2006) Longitudinal Analysis of Vasomotor Symptoms and Race/Ethnicity across the Menopausal Transition: Study of Women’s Health across the Nation (SWAN). American Journal of Public Health, 96, 1226-1235. http://dx.doi.org/10.2105/AJPH.2005. 066936
|
[5]
|
Kravitz, H.M., Zhao, X., Bromberger, J.T., et al. (2008) Sleep Disturbance during the Menopausal Transition in a Multi-Ethnic Community Sample of Women. Sleep, 31, 979-990.
|
[6]
|
Freedman, R.R. and Roehrs, T.A. (2007) Sleep Disturbance in Menopause. Menopause, 14, 826-829.
http://dx.doi.org/10.1097/gme.0b013e3180321a22
|
[7]
|
Brzezinski, A. (1997) Melatonin in Humans. New England Journal of Medicine, 336, 186-195.
http://dx.doi.org/10.1056/NEJM199701163360306
|
[8]
|
Shochat, T., Haimov, I. and Lavie, P. (1998) Melatonin: The Key to the Gate of Sleep. Annals of Medicine, 30, 109-114. http://dx.doi.org/10.3109/07853899808999392
|
[9]
|
Haimov, I., Lavie, P., Laudon, M., Herer, P., Vigder, C. and Zisapel, N. (1995) Melatonin Replacement Therapy of Elderly Insomniacs. Sleep, 18, 598-603.
|
[10]
|
Zhdanova, I.V., Lynch, H.J. and Wurtman, R.J. (1997) Melatonin—A Sleep-Promoting Hormone. Sleep, 20, 899-907.
|
[11]
|
Zhdanova, I.V. and Friedman, L. (2002) Melatonin for Treatment of Sleep and Mood Disorders. In: Mischolon, D. and Rosenbaum, J., Eds., Natural Medications for Psychiatric Disorders: Considering the Alternatives, Williams& Wilkins, 147-174.
|
[12]
|
Nowell, P.D., Mazumdar, S., Buysse, D.J., Dew, M.A., Reynolds, C.F. and Kupfer, D. (1997) Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-Analysis of Treatment Efficacy. JAMA, 278, 2170-2177.
http://dx.doi.org/10.1001/jama.1997.03550240060035
|
[13]
|
Lemoine, P., Nir, T., Laudon, M. and Zisapel, N. (2007) Prolonged-Release Melatonin Improves Sleep Quality and Morning Alertness in Insomnia Patients Aged 55 Years and Older and Has No Withdrawal Effects. Journal of Sleep Research, 16, 372-380. http://dx.doi.org/10.1111/j.1365-2869.2007.006 13.x
|
[14]
|
Lemoine, P. and Zisapel, N. (2012) Prolonged-Release Formulation of Melatonin (Circadin) for the Treatment of Insomnia. Expert Opinion on Pharmacotherapy, 13, 895-905. http://dx.doi.org/10.1517/14656566.2012.667076
|
[15]
|
Kato, K., Hirai, K., Nishiyama, K., et al. (2005) Neurochemical Properties of Ramelteon (TAK-375), a Selective MT1/ MT2 Receptor Agonist. Neuropharmacology, 48, 301-310. http://dx.doi.org/10.1016/j.neuropharm.2004.09.007
|
[16]
|
Miyamoto, M. (2009) Pharmacology of Ramelteon, a Selective MT1/MT2 Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. CNS Neuroscience & Therapeutics, 15, 32-51.
http://dx.doi.org/10.1111/j.1755-5949.2008.00066.x
|
[17]
|
Pandi-Perumal, S.R., Srinivasan, V., Spence, D.W., Moscovitch, A., Hardeland, R., Brown, G.M. and Cardinali, D.P. (2009) Ramelteon: A Review of Its Therapeutic Potential in Sleep Disorders. Advances in Therapy, 26, 613-626.
http://dx.doi.org/10.1007/s12325-009-0041-6
|
[18]
|
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M. and Cussac, D. (2003) The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2c Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways. Journal of Pharmacology and Experimental Therapeutics, 306, 954-964. http://dx.doi.org/10.1124/jpet.103.051797
|
[19]
|
Srinivasan, V., Cardinali, D.P., Pandi-Perumal, S.R. and Brown, G.M. (2011) Melatonin Agonists for Treatment of Sleep and Depressive Disorders. Journal of Experimental and Integrative Medicine, 1, 149-158.
|
[20]
|
Kennedy, S.H. and Emsley, R. (2006) Placebo-Controlled Trial of Agomelatinein the Treatment of Major Depressive Disorder. European Neuropsychopharmacology, 16, 93-100. http://dx.doi.org/10.1016/j.euroneuro.2005.09.002
|
[21]
|
Llorca, P.M. (2010) The Antidepressant Agomelatine Improves the Quality of Life of Depressed Patients: Implications for Remission. Journal of Psychopharmacology, 24, 21-26. http://dx.doi.org/10.1177/1359786810372978
|
[22]
|
Srinivasan, V., De Berardis, D., Shillcutt, S.D. and Brzezinski, A. (2012) Role of Melatonin in Mood Disorders and the Antidepressant Effects of Agomelatine. Expert Opinion on Investigating Drugs, 10, 22-1503.
|
[23]
|
Rajaratnam, S.M., Polymeropoulos, M.H., Fisher, D.M., Roth, T., Scott, C., Birznieks, G. and Klerman, E.B. (2009) Melatonin Agonist Tasimelteon (VEC-162) for Transient Insomnia after Sleep-Time Shift: Two Randomised Controlled Multicentre Trials. Lancet, 373, 482-491. http://dx.doi.org/10.1016/S0140-6736(08)61812-7
|
[24]
|
Zemlan, F.P., Mulchahey, J.J., Scharf, M.B., Mayleben, D.W., Rosenberg, R. and Lankford, A. (2005) The Efficacy and Safety of the Melatonin Agonist Beta-Methyl-6-Chloromelatonin in Primary Insomnia: A Randomized, PlaceboControlled, Crossover Clinical Trial. Journal of Clinical Psychiatry, 66, 384-390.
http://dx.doi.org/10.4088/JCP.v66n0316
|
[25]
|
Zhdanova, I.V., Wurtman, R.J., Regan, M.M., Taylor, J.A., Shi, J.P. and Leclair, O.U. (2001) Melatonin Treatment for Age-Related Insomnia. The Journal of Clinical Endocrinology & Metabolism, 86, 4727-4730.
http://dx.doi.org/10.1210/jcem.86.10.7901
|
[26]
|
Haimov, I., Laudon, M., Zisapel, N., Souroujon, M., Nof, D., Shlitner, A., Herer, P., Tzischinsky, O. and Lavie, P. (1994) Sleep Disorders and Melatonin Rhythms in Elderly People. British Medical Journal, 309, 167.
http://dx.doi.org/10.1136/bmj.309.6948.167
|
[27]
|
Hughes, R.J. and Badia, P. (1997) Sleep-Promoting and Hypothermic Effects of Daytime Melatonin Administration in Humans. Sleep, 20, 124-131.
|
[28]
|
Leger, D., Laudon, M. and Zisapel, N. (2004) Nocturnal 6-Sulfatoxymelatonin Excretion in Insomnia and Its Relation to the Response to Melatonin Replacement Therapy. American Journal of Medicine, 116, 91-95.
http://dx.doi.org/10.1016/j.amjmed.2003.07.017
|
[29]
|
Vakkuri, O., Kivela, A., Leppaluoto, J., Valtonen, M. and Kauppila, A. (1996) Decrease in Melatonin Precedes FollicleStimulating Hormone Increase during Perimenopause. European Journal of Endocrinology, 135, 188-192.
http://dx.doi.org/10.1530/eje.0.1350188
|
[30]
|
Cajochen, C., Jewett, M.E. and Dijk, D.J. (2003) Human Circadian Melatonin Rhythm Phase Delay during a Fixed Sleep-Wake Schedule Interspersed with Nights of Sleep Deprivation. Journal of Pineal Research, 35, 149-157.
http://dx.doi.org/10.1034/j.1600-079X.2003.00072.x
|
[31]
|
Lavie, P. (1997) Melatonin: Role in Gating Nocturnal Rise in Sleep Propensity. Journal of Biological Rhythms, 12, 657-665. http://dx.doi.org/10.1177/074873049701200622
|
[32]
|
Brzezinski, A., Vangel, M.G., Wurtman, R.J., Norrie, G., Zhdanova, I., Ben-Shushan, A. and Ford, I. (2005) Effects of Exogenous Melatonin on Sleep: A Meta-Analysis. Sleep Medicine Reviews, 9, 41-50.
http://dx.doi.org/10.1016/j.smrv.2004.06.004
|
[33]
|
Buscemi, N., Vandermeer, B., Hooten, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T.P. and Vohra, S. (2005) The Efficacy and Safety off Exogenous Melatonin for Primary Sleep Disorders: A Meta-Analysis. Journal of General Internal Medicine, 20, 1151-1158. http://dx.doi.org/10.1111/j.1525-1497.2005.0243.x
|
[34]
|
Braam, W., Smits, M.G., Didden, R., Korzilius, H., Van Geijlswijk, I.M. and Curfs, L.M. (2009) Exogenous Melatonin for Sleep Problems in Individuals with Intellectual Disability: A Meta-Analysis. Developmental Medicine & Child Neurology, 51, 340-349. http://dx.doi.org/10.1111/j.1469-8749. 2008.03244.x
|
[35]
|
Turek, F.W. and Gillette, M.U. (2004) Melatonin, Sleep, and Circadian Rhythms: Rationale for Development of Specific Melatonin Agonists. Sleep Medicine, 5, 523-532. http://dx.doi.org/10.1016/j.sleep.2004.07.009
|
[36]
|
Garfinkel, D., Zorin, M., Wainstein, J., Matas, Z., Laudon, M. and Zisapel, N. (2011) Efficacy and Safety of Prolonged-Release Melatonin in Insomnia Patients with Diabetes: A Randomized, Double-Blind, Crossover Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 4, 307-313.
|
[37]
|
Dolev, Z. (2011) Case Series of Perimenopausal Women with Insomnia Treated with Mirtazapine Followed by Prolonged-Release Melatonin Add-On and Monotherapy. Archives of Women’s Mental Health, 14, 269-273.
http://dx.doi.org/10.1007/s00737-011-0205-7
|
[38]
|
Saper, C.B., Lu, J., Chou, T.C. and Gooley, J. (2005) The Hypothalamic Integrator for Circadian Rhythms. Trends in Neurosciences, 28, 152-157. http://dx.doi.org/10.1016/j.tins.2004.12.009
|
[39]
|
Saper, C.B., Scammell, T.E. and Lu, J. (2005) Hypothalamic Regulation of Sleep and Circadian Rhythms. Nature, 437, 1257-1263. http://dx.doi.org/10.1038/nature04284
|
[40]
|
Kalsbeek, A., Perreau-Lenz, S. and Buijs, R.M. (2006) A Network of (Autonomic) Clock Outputs. Chronobiology International, 23, 521-535. http://dx.doi.org/10.1080/07420520600651073
|
[41]
|
Reghunandanan, V. and Reghunandanan, R. (2006) Neurotransmitters of the Suprachiasmatic Nuclei. Journal of Circadian Rhythms, 4, 2. http://dx.doi.org/10.1186/1740-3391-4-2
|
[42]
|
Reppert, S.M., Weaver, D.R. and Ebisawa, T. (1994) Cloning and Characterization of a Mammalian Melatonin Receptor that Mediates Reproductive and Circadian Responses. Neuron, 13, 1177-1185.
http://dx.doi.org/10.1016/0896-6273(94)90055-8
|
[43]
|
Dubocovich, M.L., Delagrange, P., Krause, D.N., Sugden, D., Cardinali, D.P. and Olcese, J. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors. Pharmacological Reviews, 62, 343-380. http://dx.doi.org/10.1124/pr.110.002832
|
[44]
|
Kato, K., Hirai, K., Nishiyama, K., Uchikawa, O., Fukatsu, K., Ohkawa, S., Kawamata, Y., Hinuma, S. and Miyamoto, M. (2005) Neurochemical Properties of Ramelteon (TAK-375), a Selective MT1/MT2 Receptor Agonist. Neuropharmacology, 48, 301-310. http://dx.doi.org/10.1016/j.neuropharm.2004. 09.007
|
[45]
|
Miyamoto, M. (2009) Pharmacology of Ramelteon, a Selective MT1/MT2 Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. CNS Neuroscience & Therapeutics, 15, 32-51.
http://dx.doi.org/10.1111/j.1755-5949.2008.00066.x
|
[46]
|
Cajochen, C. (2005) TAK-375 Takeda. Current Opinion in Investigational Drugs, 6, 114-121.
|
[47]
|
Greenblatt, D.J., Harmatz, J.S. and Karim, A. (2007) Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2. Journal of Clinical Pharmacology, 47, 485-496. http://dx.doi.org/10.1177/0091270006298602
|
[48]
|
Stevenson, S., Bryson, S., Amayke, D. and Hibberd, M. (2004) Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ramelteon (TAK-375) in Healthy Male Subjects. Clinical Pharmacology & Therapeutics, 75, 22.
|
[49]
|
Wu, Y.H., Zhou, J.N., Balesar, R., Unmehopa, U., Bao, A., Jockers, R., Van Heerikhuize, J. and Swaab, D.F. (2006) Distribution of MT1 melatonin Receptor Immune-Reactivity in the Human Hypothalamus and Pituitary Gland: Colocalization of MT1 with Vasopressin, Oxytocin, and Corticotropin-Releasing Hormone. Journal of Comparative Neurology, 499, 897-910. http://dx.doi.org/10.1002/cne.21152
|
[50]
|
Savaskan, E., Olivieri, G., Meier, F., Brydon, L., Jockers, R., Ravid, R., Wirz-Justice, A. and Muller-Spahn, F. (2002) Increased Melatonin 1a-Receptor Immunoreactivity in the Hippocampus of Alzheimer’s Disease Patients. Journal of Pineal Research, 32, 59-62. http://dx.doi.org/10.1034/j.1600-079x.2002.00841.x
|
[51]
|
Savaskan, E., Ayoub, M.A., Ravid, R., Angeloni, D., Fraschini, F., Meier, F., Eckert, A., Muller-Spahn, F. and Jockers, R. (2005) Reduced Hippocampal MT2 Melatonin Receptor Expression in Alzheimer’s Disease. Journal of Pineal Research, 38, 10-16. http://dx.doi.org/10.1111/j.1600-079X.2004.00169.x
|
[52]
|
Savaskan, E., Jockers, R., Ayoub, M., Angeloni, D., Fraschini, F., Flammer, J., Eckert, A., Muller-Spahn, F. and Meyer, P. (2007) The MT2 Melatonin Receptor Subtype Is Present in Human Retina and Decreases in Alzheimers Disease. Current Alzheimer Research, 4, 47-51. http://dx.doi.org/10.2174/156720507779939823
|
[53]
|
Brunner, P., Sozer-Topcular, N., Jockers, R., Ravid, R., Angeloni, D., Fraschini, F., Eckert, A., Müller-Spahn, F. and Savaskan, E. (2006) Pineal and Cortical Melatonin Receptors MT1 and MT2 Are Decreased in Alzheimer’s Disease. European Journal of Histochemistry, 50, 311-316.
|
[54]
|
Pandi-Perumal, S.R., Srinivasan, V., Spence, D.W., Moscovitch, A., Hardeland, R., Brown, G.M. and Cardinali, D.P. (2009) Ramelteon: A Review of Its Therapeutic Potential in Sleep Disorders. Advances in Therapy, 26, 613-626.
http://dx.doi.org/10.1007/s12325-009-0041-6
|
[55]
|
Srinivasan, V., Pandi-Perumal, S.R., Trahkt, I., Spence, D.W., Poeggeler, B., Hardeland, R. and Cardinali, D.P. (2009) Melatonin and Melatonergic Drugs on Sleep: Possible Mechanisms of Action. International Journal of Neuroscience, 119, 821-846. http://dx.doi.org/10.1080/00207450802328607
|
[56]
|
Yukuhiro, N., Kimura, H., Nishikawa, H., Ohkawa, S., Yoshikubo, S. and Miyamoto, M. (2004) Effects of Ramelteon (TAK-375) on Nocturnal Sleep in Freely Moving Monkeys. Brain Research, 1027, 59-66.
http://dx.doi.org/10.1016/j.brainres.2004.08.035
|
[57]
|
France, C.P., Weltman, R.H., Koek, W., Cruz, C.M. and Mcmahon, L.R. (2006) Acute and Chronic Effects of Ramelteon in Rhesus Monkeys (Macaca mulatta): Dependence Liability Studies. Behavioral Neuroscience, 120, 535-541. http://dx.doi.org/10.1037/0735-7044.120.3.535
|
[58]
|
Roth, T., Seiden, D., Sainati, S., Wang-Weigand, S., Zhang, J. and Zee, P. (2006) Effects of Ramelteon On PatientReported Sleep Latency in Older Adults with Chronic Insomnia. Sleep Medicine, 7, 312-318.
http://dx.doi.org/10.1016/j.sleep.2006.01.003
|
[59]
|
Erman, M., Seiden, D., Zammit, G., Sainati, S. and Zhang, J. (2006) An Efficacy, Safety, and Dose-Response Study of Ramelteon in Patients with Chronic Primary Insomnia. Sleep Medicine, 7, 17-24.
http://dx.doi.org/10.1016/j.sleep.2005.09.004
|
[60]
|
Roth, T., Seiden, D., Wang-Weigand, S. and Zhang, J. (2007) A 2-Night,3-Period, Crossover Study of Ramelteon’s Efficacy and Safety in Older Adults with Chronic Insomnia. Current Medical Research and Opinion, 23, 1005-1014.
http://dx.doi.org/10.1185/030079907X178874
|
[61]
|
Zammit, G., Erman, M., Wang-Weigand, S., Sainati, S., Zhang, J. and Roth, T. (2007) Evaluation of the Efficacy and Safety of Ramelteon in Subjects with Chronic Insomnia. Journal of Clinical Sleep Medicine, 3, 495-504.
|
[62]
|
Mini, L., Wang-Weigand, S. and Zhang, J. (2008) Ramelteon 8 mg/d versus Placebo in Patients with Chronic Insomnia: Post Hoc Analysis of a 5-Week Trial Using 50% or Greater Reduction in Latency to Persistent Sleep as a Measure of Treatment Effect. Clinical Therapeutics, 30, 1316-1323. http://dx.doi.org/10.1016/S0149-2918(08)80056-2
|
[63]
|
Dobkin, R.D., Menza, M., Bienfait, K.L., Allen, L.A., Marin, H. and Gara, M.A. (2009) Ramelteon for the Treatment of Insomnia in Menopausal Women. Post Reproductive Health, 15, 13-18. http://dx.doi.org/10.1258/mi.2009.009002
|
[64]
|
Mayer, G., Wang-Weigand, S., Roth-Schechter, B., Lehmann, R., Staner, C. and Partinen, M. (2009) Efficacy and Safety of 6-Month Nightly Ramelteon Administration in Adults with Chronic Primary Insomnia. Sleep, 32, 351-360.
|
[65]
|
Uchimura, N., Ogawa, A., Hamamura, M., Hashimoto, T., Nagata, H. and Uchiyama, M. (2011) Efficacy and Safety of Ramelteon in Japanese Adults with Chronic Insomnia: A Randomized, Double-Blind, Placebo-Controlled Study. Expert Review of Neurotherapeutics, 11, 215-224. http://dx.doi.org/10.1586/ern.10.197
|
[66]
|
Uchiyama, M., Hamamura, M., Kuwano, T., Nagata, H., Hashimoto, T., Ogawa, A. and Uchimura, N. (2011) LongTerm Safety and Efficacy of Ramelteon in Japanese Patients with Chronic Insomnia. Sleep Medicine, 12, 127-133.
http://dx.doi.org/10.1016/j.sleep.2010.10.006
|
[67]
|
Pandi-Perumal, S.R., Srinivasan, V., Poeggeler, B., Hardeland, R. and Cardinali, D.P. (2007) Drug Insight: The Use of Melatonergic Agonists for the Treatment of Insomnia-Focus on Ramelteon. Nature Clinical Practice Neurology, 3, 221-228. http://dx.doi.org/10.1038/ncpneuro0467
|
[68]
|
Lam, R.W. (2006) Sleep Disturbances and Depression: A Challenge for Antidepressants. International Clinical Psychopharmacology, 21, S25-S29. http://dx.doi.org/10.1097/01.yic.000019 5658.91524.61
|
[69]
|
Kupfer, D.J. (2006) Depression and Associated Sleep Disturbances: Patient Benefits with a Gomelatine. European Neuropsychopharmacology, 16, S639-S643. http://dx.doi.org/10.1016/S0924-977X(06)70010-4
|
[70]
|
Guttuso, T. (2012) Effective and Clinically Meaningful Non-Hormonal Hot Flash Therapies. Maturitas, 72, 6-12.
http://dx.doi.org/10.1016/j.maturitas.2012.01.023
|
[71]
|
Eichling, P.S. and Sahni, J. (2005) Menopause Related Sleep Disorders. Journal of Clinical Sleep Medicine, 1, 291-300.
|
[72]
|
Wafford, K. and Ebert, B. (2008) Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time. Nature Reviews Drug Discovery, 7, 530-540. http://dx.doi.org/10.1038/nrd2464
|
[73]
|
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M. and Cussac, D. (2003) The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2c Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways. Journal of Pharmacology and Experimental Therapeutics, 306, 954-964. http://dx.doi.org/10.1124/jpet.103.051797
|
[74]
|
Bourin, M., Mocaer, E. and Porsolt, R. (2004) Antidepressant-Like Activity of S 20098 (Agomelatine) in the Forced Swimming Test in Rodents: Involvement of Melatonin and Serotonin Receptors. Journal of Psychiatry and Neuroscience, 29, 126-133.
|
[75]
|
Bertaina-Anglade, V., La Rochelle, C.D., Boyer, P.A. and Mocaer, E. (2006) Antidepressant-Like Effects of Agomelatine (S 20098) in the Learned Helplessness Model. Behavioural Pharmacology, 17, 703-713.
http://dx.doi.org/10.1097/FBP.0b013e3280116e5c
|
[76]
|
Fuchs, E., Simon, M. and Schmelting, B. (2006) Pharmacology of a New Antidepressant: Benefit of the Implication of the Melatonergic System. International Clinical Psychopharmacology, 21, S17-S20.
http://dx.doi.org/10.1097/01.yic.0000199456.39552.c7
|
[77]
|
Millan, M.J. (2006) Multi-Target Strategies for the Improved Treatment of Depressive States: Conceptual Foundations and Neuronal Substrates, Drug Discovery and Therapeutic Application. Pharmacology & Therapeutics, 110, 135-370.
http://dx.doi.org/10.1016/j.pharmthera.2005.11.006
|
[78]
|
Landolt, H.P. and Wehrle, R. (2009) Antagonism of Serotonergic 5-HT2A/2C Receptors: Mutual Improvement of Sleep, Cognition and Mood? European Journal of Neuroscience, 29, 1795-1809.
http://dx.doi.org/10.1111/j.1460-9568.2009.06718.x
|
[79]
|
Varcoe, T.J. and Kennaway, D.J. (2008) Activation of 5-HT2C Receptors Acutely Induces Per1 Gene Expression in the Rat SCN in Vitro. Brain Research, 1209, 19-28. http://dx.doi.org/10.1016/j.brainres.2008.02.091
|
[80]
|
Martin, J.R., Bos, M., Jenck, F., et al. (1998) 5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential. Journal of Pharmacology and Experimental Therapeutics, 286, 913-924.
|
[81]
|
Detanico, B.C., Piato, A.L., Freitas, J.J., Lhullier, F.L., Hidalgo, M.P., Caumo, W. and Elisabetsky, E. (2009) Antidepressant-Like Effects of Melatonin in the Mouse Chronic Mild Stress Model. European Journal of Pharmacology, 607, 121-125. http://dx.doi.org/10.1016/j.ejphar.2009.02.037
|
[82]
|
Mcelroy, S.L., Winstanley, E.L., Martens, B., Patel, N.C., Mori, N., Moeller, D., McCoy, J. and Keck, P.E. (2010) A Randomized, Placebo-Controlled Study of Adjunctive Ramelteon in Ambulatory Bipolar I Disorder with Manic Symptoms and Sleep Disturbance. International Clinical Psychopharmacology, 26, 48-53.
http://dx.doi.org/10.1097/YIC.0b013e3283400d35
|
[83]
|
Crupi, R., Mazzon, E., Marino, A., La Spada, G., Bramanti, P., Cuzzocrea, S. and Spina, E. (2010) Melatonin Treatment Mimics the Antidepressant Action in Chronic Corticosterone-Treated Mice. Journal of Pineal Research, 49, 123-129.
|
[84]
|
Srinivasan, V., Cardinali, D.P., Pandi-Perumal, S.R. and Brown, G.M. (2011) Melatonin Agonists for Treatment of Sleep and Depressive Disorders. Journal of Experimental and Integrative Medicine, 1, 149-158.
|
[85]
|
Loo, H., Hale, A. and Dhaenen, H. (2002) Determination of the Dose of Agomelatine, a Melatoninergic Agonist and Selective 5-HT2 Cantagonist, in the Treatment of Major Depressive Disorder: A Placebo-Controlled Dose Range Study. International Clinical Psychopharmacology, 17, 239-247. http://dx.doi.org/10.1097/00004850-200209000-00004
|
[86]
|
Kennedy, S.H. and Emsley, R. (2006) Placebo-Controlled Trial of Agomelatine in the Treatment of Major Depressive Disorder. European Neuropsychopharmacology, 16, 93-100. http://dx.doi.org/10.1016/j.euroneuro.2005.09.002
|
[87]
|
Calabrese, J.R., Guelfi, J.D. and Perdrizet-Chevallier, C. (2007) Agomelatine Adjunctive Therapy for Acute Bipolar Depression: Preliminary Open Data. Bipolar Disorders, 9, 628-635.
http://dx.doi.org/10.1111/j.1399-5618.2007.00507.x
|
[88]
|
Llorca, P.M. (2010) The Antidepressant Agomelatine Improves the Quality of Life of Depressed Patients: Implications for Remission. Journal of Psychopharmacology, 24, 21-26. http://dx.doi.org/10.1177/1359786810372978
|
[89]
|
Di Giannantonio, M., Di Iorio, G., Guglielmo, R., De Berardis, D., Conti, C.M., Acciavatti, T., Cornelio, M. and Martinotti, G. (2011) Major Depressive Disorder, Anhedonia and Agomelatine: An Open-Label Study. Journal of Biological Regulators and Homeostatic Agents, 25, 109-114.
|
[90]
|
Lopes, M.C., Quera-Salva, M.A. and Guilleminault, C. (2005) Cycling Alternating Pattern in the NREM Sleep of Patients Within Major Depressive Disorder: Baseline Results and Change Overtime with a New Antidepressant. Sleep Medicine, 6, 87-88.
|
[91]
|
Lopes, M.C., Quera-Salva, M.A. and Guilleminault, C. (2007) Non-REM Sleep Instability in Patients with Major Depressive Disorder: Subjective Improvement and Improvement of Non-REM Sleep Instability with Treatment (Agomelatine). Sleep Medicine, 9, 33-41. http://dx.doi.org/10.1016/j.sleep.2007.01.011
|
[92]
|
Hardeland, R., Poeggeler, B., Srinivasan, V., Trakht, I., Pandi-Perumal, S.R. and Cardinali, D.P. (2008) Melatonergic Drugs in Clinical Practice. Arzneimittel-Forschung, 58, 1-10.
|
[93]
|
Kasper, S., Hajak, G., Wulff, K., et al. (2010) Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients with Major Depressive Disorder: A Randomized, Double-Blind Comparison with Sertraline. Journal of Clinical Psychiatry, 71, 109-120.
http://dx.doi.org/10.4088/JCP.09m05347blu
|
[94]
|
European Food Safety Authority (2011) Scientific Opinion on the Substantiation of a Health Claim Related to Melatonin and Reduction of Sleep Onset Latency (ID 1698, 1790, 4080) Pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 9, 2241.
|
[95]
|
Wilson, S.J., Nutt, D.J., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.J., Espie, C., Gringras, P., Hajak, G., Idzikowski, C., Krystal, A., Nash, J., Selsick, H., Sharpley, A. and Wade, A. (2010) British Association for Psychopharmacology Consensus Statement on Evidence-Based Treatment of Insomnia, Parasomnias and Circadian Rhythm Disorders. Journal of Psychopharmacology, 24, 1577-1601.
http://dx.doi.org/10.1177/0269881110379307
|